Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children

• Váldodahkkit: Josiah Ryman (Dahkki), Jeffrey R. Sachs (Dahkki), Ka Lai Yee (Dahkki), Natalie Banniettis (Dahkki), Jessica Weaver (Dahkki), Thomas Weiss (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

ABSTRACTBackground Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent PCV (PCV13). Without efficacy or real-world vaccine effectiveness...